Synergistic Combinations

Combination strategies for withaferin A, including chemotherapy, immunotherapy, and scheduling conflicts.

WFA is a rational combination partner because it targets resistance biology that many standard therapies do not fully address. That does not mean every mechanistically appealing combination is clinically ready.

Most combination evidence is preclinical. Safety cannot be inferred from synergy alone.

Chemotherapy combinations

Cisplatin and carboplatin in ovarian cancer

This is the strongest chemotherapy combination signal.

WFA plus cisplatin acts synergistically in ovarian cancer models through complementary pressure on ROS handling, DNA damage response, and cancer stem cell survival. In orthotopic mouse models, the combination reduced tumour growth and blocked metastasis more effectively than either agent alone.

A key point is that WFA depleted CSC-enriched populations that cisplatin alone tended to spare or enrich.

Paclitaxel in non-small cell lung cancer

WFA plus paclitaxel has shown synergy in NSCLC cell lines and early animal work. The combination reduced proliferation, migration, and invasion more than either agent alone.

Doxorubicin and liposomal doxorubicin

The most clinically advanced current trial uses Ashwagandha extract with liposomal doxorubicin in recurrent ovarian cancer. This is relevant but does not isolate purified WFA.

Temozolomide and radiotherapy in glioblastoma

In glioblastoma models, WFA has increased radiosensitivity and potentiated cytotoxic stress through HSP90/Akt/mTOR disruption and proteostasis effects. This remains early.

Oxaliplatin in pancreatic cancer

Cell-line work supports synergy through ROS-mediated suppression of the PI3K/AKT axis. Human relevance remains uncertain.

Sorafenib in thyroid and hepatocellular cancer

Preclinical work supports synergy, including relevance to ferroptosis and EMT in resistant settings.

Immunotherapy combinations

Anti-PD-L1 therapy

This is the most biologically coherent current combination use case.

WFA induces immunogenic cell death and can raise tumour PD-L1 through ROS-mediated signalling. In syngeneic mouse models, WFA plus anti-PD-L1 outperformed either treatment alone without added toxicity.

Anti-PD-1 therapy

The rationale is similar but less directly tested. Recent review work places WFA among phytochemicals that may improve response in otherwise checkpoint-resistant tumours.

Targeted therapy combinations

mTOR inhibitors

This combination needs caution.

mTOR inhibitors activate TFEB, increase lysosomal biogenesis, and can counteract WFA's autophagy-blocking strategy if given at the same time. If both are used, timing separation matters.

CDK4/6 inhibitors

Available extract-level interaction data suggests major CYP-mediated pharmacokinetic interactions are unlikely at standard exposure. The more practical concern is overlapping toxicity, especially liver stress and blood count monitoring.

For related context, see CDK4/6 Options and Supplement Considerations.

Natural compound combinations — scheduling conflicts

Some commonly used compounds can directly undermine WFA's autophagy-blocking effect by activating TFEB and restoring lysosomal capacity.

Compound	Mechanism of conflict	Practical action
Liposomal or high-dose curcumin	Direct `TFEB` binding independent of mTOR status	Keep out of the active WFA window
Resveratrol	`mTOR` inhibition leading to `TFEB` activation	Separate from WFA dosing
Quercetin	`TFEB` pathway activation	Separate from WFA dosing
Metformin	`AMPK → mTOR → TFEB` axis	Consider timing separation when autophagy blockade is a primary goal
Sulforaphane	Direct `TFEB` agonism	Separate from WFA dosing

What about proton pump inhibitors and fasting?

PPIs raise lysosomal pH and may act in the same direction as WFA rather than opposing it.

Fasting is more nuanced. mTOR inhibition can activate TFEB, but the broader metabolic stress of fasting may still complement WFA by making tumour cells more dependent on the very recycling pathways WFA disrupts.

Practical take

The best-supported combination settings today are:

platinum-based ovarian cancer work
paclitaxel-based NSCLC work
checkpoint inhibitor sensitisation in lung cancer models

The main scheduling caution is simultaneous use with strong TFEB activators when autophagy blockade is the intended mechanism.

Key references

Kakar S. et al. — cisplatin synergy and ovarian cancer stem cell targeting.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4218168/

Saneja A. et al. — paclitaxel combinations in non-small cell lung cancer.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7185067/

University of Louisville — ovarian cancer trial of Ashwagandha extract plus liposomal doxorubicin.
https://ctv.veeva.com/study/combination-therapy-for-recurrent-ovarian-cancer

Sarin N. et al. — oxaliplatin and WFA synergy in pancreatic cancer chemoresistance.
https://www.sciencedirect.com/science/article/pii/S0753332218330701

Guo J. et al. — sorafenib-combination context and Nrf2/ferroptosis relevance in withanolide review literature.
https://onlinelibrary.wiley.com/doi/10.1002/ptr.8090

Banerjee S. et al. — checkpoint inhibitor sensitisation in non-small cell lung cancer.
https://pmc.ncbi.nlm.nih.gov/articles/PMC10295988/

Wang W. et al. — TFEB-activating natural products and lysosomal regulation.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7684757/

Teschke R. et al. — herb-drug interaction and safety review context for Withania somnifera.
https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1658265/full

Access and availability:
Source: MCS Formulas, “Withaferin A Pro Liposomal.”
50 mg WFA per capsule. Available via healthcare professional request.
https://www.mcsformulas.com/vitamins-supplements/withaferin-a-pro-liposomal/ref/14